Q-omics provides the consensus-scored LYPD5 profile across patient tissues and cancer cell-line models. LYPD5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LYPD5 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, LYPD5 RNA expression shows 14,745 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, COAD, and KIRP as cancer lineages where LYPD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYPD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYPD5 survival associations across molecular data types. LYPD5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYPD5 RNA expression–survival associations across cancer types. High LYPD5 expression shows unfavorable associations in PAAD and LAML, but favorable associations in KIRC, CESC, UVM and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LYPD5 RNA expression.
This table summarizes LYPD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LYPD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYPD5 shows lower tumor expression in KICH and higher tumor expression in COAD, THCA, BRCA, BLCA and KIRC. The COAD box plot shows higher LYPD5 RNA expression in tumor versus normal tissue (log2 FC = +1.023, t-test p < 0.001).
This table shows molecular features associated with LYPD5 in patient tissues and cancer cell lines. In patient samples, LYPD5 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, LYPD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LUNG_NSCLC_LUAD.
